Clinical Trial

A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer

Study acronym: INAVO-CRC

Withdrawn Phase 2

View on ClinicalTrials.gov →

Why the trial stopped

Sponsor's decision

Summary

This is a blinded Phase 2 study designed to evaluate the safety and efficacy of inavolisib with bevacizumab and chemotherapy, in participants with metastatic colorectal cancer (mCRC) whose tumors have a PIK3CA mutation. The study has a safety run-in period followed by a randomized period.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-01-06.

Status change: Not Yet Recruiting → Withdrawn 2026-02-05

Trial Details

NCT Number	NCT07323576
Lead Sponsor	Hoffmann-La Roche
Conditions	Colorectal Cancer
Start Date	2026-02-01
Primary Completion	2029-03-01 (estimated)
Study Completion	2031-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-09